{
    "nctId": "NCT01451632",
    "briefTitle": "A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers",
    "officialTitle": "A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers",
    "overallStatus": "COMPLETED",
    "conditions": "Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Other Tumors With EGFR Dependence",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 48,
    "primaryOutcomeMeasure": "Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Cetuximab and the MM-121 Plus Cetuximab Plus Irinotecan Combination",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* No standard options remaining\n* Adequate liver and kidney functions\n* 18 years of age or above\n\nExclusion Criteria:\n\n* History of any secondary active cancer in the last 3 years.\n* Pregnant or breast feeding\n* History of severe allergic reactions or contraindications to cetuximab or irinotecan",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}